Ultragenyx Pharmaceutical clinical trials we track

Check company identity source

Phase 3 8 trials

Phase 2 / 3 2 trials

Phase 2 4 trials

Phase 1 / 2 2 trials

TrialDrugs studiedStatusPrimary completion
First-in-human Study of UX016 in GNEMNCT07511556UX016Recruiting2028-12Estimated
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson DiseaseNCT04884815Standard of Care (SOC)Active not recruiting2029-03Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2026-09-17DayUX111Ultragenyx Pharmaceutical Inc · RAREFDA CBER biologic approvalFDA approval decisionIndicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.Open original source
Read source excerpt

{"product": "Fayuvi rebisufligene etisparvovec-hopf", "indication": "Indicated for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.", "application": "125845/0", "manufacturer": "Ultragenyx Pharmaceutical Inc.", "date": "2026-09-17"}

First seen: 03 Nov 2026 · Evidence last checked: 03 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 60 participants (planned). After: 55 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jan 2030. After: 30 Oct 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source
Long-term Extension of GTX-102 in Angelman Syndrome

NCT06415344 · Ultragenyx Pharmaceutical Inc

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 255 participants (planned). After: 66 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Feb 2029. After: 30 Oct 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Percent Change from Baseline to Week 48 in Daily Cornstarch Intake Time frame: Baseline, Week 48. After: Measure: Main Study: Percent Change From Baseline to Week 48 in Daily Cornstarch Intake (Grams) Description: The least square (LS) mean and standard error (SE) are based on mixed-model for repeated measures (MMRM) analysis. Time frame: Baseline, Weeks 24, 30, 36, 42 and 48 Measure: Japan Cohort: Percent Change From Baseline to Week 48 in Daily Cornstarch Intake (Grams) Time frame: Baseline, Weeks 24, 30, 36, 42 and 48.

Actual enrollment increased by 3 participants

Before: 49 participants (actual). After: 52 participants (actual).

Check registry source
Long-term Extension of GTX-102 in Angelman Syndrome

NCT06415344 · Ultragenyx Pharmaceutical Inc

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency, Severity, and Relationship to Investigational Drug of Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs). After: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs).

Check registry source